

## **Last Five-year research work of Dr. Amit Awasthi:**

1. Karwacz K, Miraldi ER, Pokrovskii M, Madi A, Yosef N, Wortman I, Chen X, Watters A, Carriero N, **Awasthi A**, Regev A, Bonneau R, Littman D, Kuchroo VK. Critical role of IRF1 and BATF in preparing the chromatin landscape during Tr1 differentiation. **Nature Immunology** **2017**, 18(4):412-421. doi: 10.1038/ni.3683.
2. Malik S, Sadhu S, Elesela S, Pandey R, Rathod D, Amanpreet Chawla, Sharma D, Ghosh B, Ahuja V, **Awasthi A**. Transcription factor Foxo1 essential for differentiation of IL-9+ T helper cells. **Nature Communications** **2017**, 8(1):815. doi: 10.1038/s41467-017-00674-6.
3. Goyal S, Rampal R, Kedia S, Mahajan S, Bopanna S, Yadav D, Jain S, Singh A, Wari NM, Makharia G, **Awasthi A\***, Ahuja V. Urinary potassium is a potential biomarker of disease activity in Ulcerative colitis and displays in vitro immunotolerant role. **Scientific Reports** **2017**. (\*Shared senior author), Dec 22;7(1):18068. doi: 10.1038/s41598-017-18046-x.
4. Malik S, **Awasthi A**. Transcriptional Control of Th9 Cells: Role of Foxo1 in Interleukin-9 Induction. **Front Immunol** **2018** May 9;9: 995. doi: 10.3389/fimmu.2018.00995.
5. Roy S, **Awasthi A**. Metabolic checkpoints in differentiation of helper T cells in tissue inflammation. **Front in Immunol** **2019**, 9:3036. doi: 10.3389/fimmu.2018.03036.
6. Roy S, **Awasthi A**. ATP Triggers Human Th9 Cell Differentiation via Nitric Oxide-Mediated mTOR-HIF1 $\alpha$  Pathway. **Front Immunol**. 2019, 10:1120. doi: 10.3389/fimmu.2019.01120.
7. Roy S and **Awasthi A**. Emerging roles of non-coding RNAs in T cell differentiation and functions in autoimmune diseases. **International Review of Immunology** **2019**, 38:232-245. doi: 10.1080/08830185.2019.
8. Chandwaskar R, **Awasthi A**, Emerging roles of Th9 cells as an anti-tumor helper T cells. **International Review of Immunology** **2019**, 38(5):204-211. doi: 10.1080/08830185.2019.
9. Sohail A, Abbas ZA, Ahuja V, **Awasthi A\***, Srikanth CV. DeSUMOylase SENP7 mediated epithelial signalling triggers intestinal inflammation via expansion of Gamma-delta T cell. **Cell Repts** **2019**, Dec 10;29(11):3522-3538.e7. doi: 10.1016/j.celrep.2019.11.028. (\*Co-corresponding author)
10. Pal S, Medatwal N, Kumar S, Kar A, Komalla V, Yavvari PS, Mishra D, Rizvi ZA, Nandan S, Malakar D, Pillai M, **Awasthi A**, Das P, Sharma RD, Srivastava A, Sengupta S, Dasgupta U, Bajaj A. A localized chimeric hydrogel therapy combats tumor progression through alteration of sphingolipid metabolism. **ACS Central Science** **2019**, 5(10):1648-1662. doi:10.1021/acscentsci.9b00551.
11. **Awasthi A**, Kumar H. T cell subtypes and its therapeutic potential in autoimmune diseases and cancer. **International Review of Immunology** **2019**, 38:181-182. doi: 10.1080/08830185.2019.
12. Goswami R, **Awasthi A**. T Cell Differentiation and Function in Tissue Inflammation. **Front Immunol**. **2020** Feb 21;11:289. doi: 10.3389/fimmu.2020.00289.
13. Roy S, Asthana A, Goyal R, Yadav AK, **Awasthi A**. Proteome analysis revealed the essential functions of PP2A in the induction of Th9 cells. **Scientific Reports** **2020**, 10:10992. doi: 10.1038/s41598-020-67845-2.
14. Samal S, Shrivastava T, Sonkusre P, Rizvi ZA, Kumar R, Ahmed S, Bansal M, Chauhan K, Pokhrel S, Tambare P, **Awasthi A**. Tetramerizing tGCN4 Domain Facilitates Production of Influenza A H1N1 M2e Higher Order Soluble Oligomers that Show Enhanced Immunogenicity In vivo. **Journal of Biological Chemistry** **2020**, jbc.RA120.013233. doi: 10.1074/jbc.RA120.013233.
15. Zhang H, Madi A, Yosef N, Chihara N, **Awasthi A**, Pot C, Lambden C, Srivastava A, Burkett PR, Nyman J, Christian E, Etminan Y, Lee A, Strohm H, Xia J, Karwacz K, Thakore PI, Acharya

N, Schnell A, Wang W, Apetoh L, Rozenblatt-Rosen O, Anderson AC, Regev A, Kuchroo VK. IL-27 driven transcriptional network identifies regulators of IL-10 expression across T helper cell subset. **Cell Reps** **2020**, 33:108433. doi: 10.1016/j.celrep.2020.108433.

16. Rampal R, Saurabh Kedia, **Awasthi A**, Ahuja A. Retinoic acid is elevated in the mucosa of patients with active ulcerative colitis and displays a pro-inflammatory role by augmenting IL-17 and IFN $\gamma$  production. **Inflammatory Bowel Diseases**, **2021**. 27:74-83. doi: 10.1093/ibd/izaa121
17. Mittal L, Srivastava M, Kumari A, Tonk RK, **Awasthi A\***, Asthana S. The interplay among structural stability, plasticity and energetics is determined by conformational attuning of flexible loops of PD-1. **Journal of Chemical Information and Modelling**, **2021**. 61:358-384. doi: 10.1021/acs.jcim.0c01080. \*Co-corresponding author
18. Roy S, Rizvi ZA, Clarke A, Macdonald F, Pandey A, Zaiss D, Dr. Simon KA, **Awasthi A**. EGFR-HIF1 $\alpha$  signaling positively regulates the differentiation of IL-9 producing T helper cells. **Nature Communication**, **2021**. 12(1):3182. doi: 10.1038/s41467-021-23042-x
19. Sadhu S, Rizvi ZA, Pandey RP, Dalal R, Rathore DK, Kumar B, Pandey M, Kumar Y, Goel R, Maiti TK, Tiwari A, Pandey AK, **Awasthi A**. EGFR-HIF1 $\alpha$  axis is essential for the intracellular survival of *Salmonella*. **Front Immunol**. **2021**, 12:648710. doi: 10.3389/fimmu.2021.648710.
20. Vishwakarma P, Yadav N, Rizvi ZA, Khan NA, Chiranjivi A, Shrivastava T, Bansal M, Dwivedi P, Kumar R, **Awasthi A**, Ahmed S, Samal S. Characterization of SARS-CoV2 Spike Protein Synthetic Peptides as potential targets for vaccine and therapeutics. **Front Immunol**. **2021**, 12:613045. doi: 10.3389/fimmu.2021.613045.
21. Chauhan S, Rathore DK, Lacroix-Desmazes S, Gupta N, **Awasthi A**, Vrati S, Kalia M. Japanese encephalitis virus infected human monocyte-derived dendritic cells activate a transcriptional network leading to an antiviral inflammatory response. **Front Immunol**. **2021**, 12:638694. doi: 10.3389/fimmu.2021.638694.
22. Ganneru B, Jogdand H, Dharam VK, Mulugu N, Prasad B S, Srinivas VK, Ella K, Ravikrishnan R, **Awasthi A**, Jose J, Rao P, Kumar D, Abraham P, Yadav P, Sapkal G, Shete A, Deshpande GR, Mohandas S, Basu A, Gupta N, Bhargava B, Mohan K, Ella R. Evaluation of Safety and Immunogenicity of an Adjuvanted, TH-1 Skewed, Whole Virion Inactivated SARS-CoV-2 Vaccine - BBV152. **iScience**, **2021**, 24 (4):102298. doi: 10.1016/j.isci.2021.102298
23. Lin X, Gaudino S, Roy S, Castillo P, Elsegeiny W, Wakabayashi N, Oury TD, Pociask D, Chen K, **Awasthi A**, Kolls JK and Kumar P. Nrf2 differentially regulates IL-22 and IL-17A response in CD4<sup>+</sup> T cells through Ahr and SOD3 axis. **Journal of Immunology**, **2021**. 206 (7); 1540-1548; doi: 10.4049/jimmunol.1900656.
24. Yadav N, Vishwakarma P, Khatri R, Siddiqui G, **Awasthi A**, Ahmed S, Samal S. Comparative Immunogenicity analysis of Intra dermal and Intra muscular administration of SARS-CoV2 RBD epitope peptide-based Immunogen. **Microbes and Infection**, **2021**. 23(4-5):104843. doi: 10.1016/j.micinf.2021.104843.
25. Shrivastava T, Singh B, Rizvi ZA, Verma R, Goswami S, Vishwakarma P, Jakhar K, Sonar S, Mani S, Bhattacharyya S, **Awasthi A**, Surjit M. Comparative immunomodulatory evaluation of the receptor binding domain of SARS CoV-2 spike protein; a potential vaccine candidate, imparts potent humoral and Th1 type of immune response in a mouse model. **Front Immunol**. **2021**, 12:641447. doi: 10.3389/fimmu.2021.641447.
26. Rizvi ZA, Dalal R, Sadhu S, Kumar Y, Kumar S, Gupta SK, Tripathy MR, Rathore DK, **Awasthi A**. High salt diet mediates interplay between NK cells and gut microbiota to induce potent tumor immunity. **Science Advances**, **2021**. 7(37):eabg5016. doi: 10.1126/sciadv.abg5016.
27. Mittal L, Tonk RK, **Awasthi A**, Asthana S. Targeting cryptic-orthosteric site of PD-L1 for inhibitor identification using structure-guided approach. **Arch Biochem Biophys**. **2021**, 713:109059. doi: 10.1016/j.abb.2021.109059

28. Rizvi ZA, Tripathy MR, Sharma N, Goswami S, Srikanth N, Sastry JLN, Mani S, Surjit M, **Awasthi A\***, Dikshit M. Effect of prophylactic use of intra-nasal oil formulation in the hamster model of Covid19. **Frontiers in Pharmacology** **2021**, Oct 14;12:746729. doi: 10.3389/fphar.2021.746729. \*Co-corresponding author
29. Thiruvengadam R, **Awasthi A**, Medigeshi GR, Bhattacharya S, Mani S, Sivasubbu S, Shrivastava S, Samal S, Murugesan DR, Desiraju BK, Kshetrapal P, Pandey R, Scaria V, Malik PK, Taneja J, Binayke A, Vohra T, Zaheer A, Rathore D, Khan NA, Shaman H, Ahmed S, Kumar R, Deshpande S, Subramani C, Wadhwa N, Gupta N, Pandey AK, Bhattacharya J, Agrawal A, Vrati S, Bhatnagar S, Garg PK. Cellular Immune Responses are Preserved and may Contribute to Vaccine Effectiveness of ChAdOx1 nCoV-19 vaccine against SARS-CoV-2 infection during the delta (B.1.617.2) variant surge in India: a test-negative, case-control study and a mechanistic study of post-vaccination immune responses. **Lancet Infectious Disease** **2021**, Nov 25:S1473-3099(21)00680-0. doi: 10.1016/S1473-3099(21)00680-0.
30. Thiruvengadam R, Binayke A, **Awasthi A**. SARS-CoV-2 delta variant – a persistent threat to the effectiveness of vaccines. **Lancet Infectious Disease**, **2022**. **22**(3):301-302. doi: 10.1016/S1473-3099(21)00697-6.
31. Suri C, **Awasthi A\***, Asthana S. RoR $\square$ t agonist, inverse agonists and allosteric inhibitors- a crystallographic landscape. **Drug Discovery Today** **2022**, Nov 24:S1359-6446(21)00503-1. doi: 10.1016/j.drudis.2021.11.022. \*Co-corresponding author
32. Rizvi ZA, Dalal R, Sadhu S, Binayke A, Dandotiya J, Kumar Y, Shrivastava T, Gupta SK, Aggarwal S, Tripathy M, Rathore DK, Yadav AK, Medigeshi GR, Pandey A, Samal S, Asthana A, **Awasthi A**. Golden syrian hamster as a model to study cardiovascular complications associated with SARS-CoV2 infection. **eLife**, **2022**. Jan 11;11:e73522. doi: 10.7554/eLife.73522.
33. Thiruvengadam R, **Awasthi A**, Bhatnagar S, Garg PK. Effectiveness of ChAdOx1 nCoV-19 vaccine during the delta (B.1.617.2) variant surge in India - Authors' reply. **Lancet Infectious Disease** **2022**, **22**(4):447. doi: 10.1016/S1473-3099(22)00120-7.
34. Hingankar N, Deshpande S, Das P, Rizvi ZA, Burns A, Barman S, Zhao F, Ansari MY, Mukherjee S, Torres JL, Chattopadhyay S, Mehdi F, Sutar J, Rathore DK, Pargai K, Singh J, Sonar S, Jakhar K, Bhattacharyya S, Mani S, Singh S, Dandotiya J, Kshetrapal P, Thiruvengadam R, Batra G, Medigeshi G, Ward AB, Bhatnagar S, **Awasthi A**, Sok D, Bhattacharya J. A combination of potentially neutralizing monoclonal antibodies isolated from an Indian convalescent donor protects against the SARS-CoV-2 delta variant. **Plos Pathogens**. **2022**
35. Mittal L, Tonk R, **Awasthi A**, Asthana S. Traversing through the dynamic protein-protein interaction landscape and conformational plasticity of PD-1 for small molecule discovery. **Medicinal Chemistry**, **2022**. doi: 10.1021/acs.jmedchem.2c00176
36. Khatri R, Parray HA, Agrahari AK, Rizvi ZA, Kaul R, Raj S, Asthana S, Mani S, Sweet Samal, **Awasthi A**, Ahmed S. Designing and characterization of a SARS-CoV-2 immunogen with receptor binding motif grafted on a protein scaffold: An epitope-focused vaccine approach. **International Journal of Biological Macromolecules**, **2022**. **22**:S0141-8130(22)00861-3. DOI: 10.1016/j.ijbiomac.2022.04.148.
37. Kumar CS, Singh B, Rizvi ZA, Parray HA, Verma JK, Ghosh S, Mukhopadhyay A, **Awasthi A**, Shrivastava T, Banerjee M. Virus-like particles of SARS-CoV-2 as virus surrogates: morphology, immunogenicity, and internalization in neuronal cells. **ACS Infectious Diseases**, **2022**. doi.org/10.1021/acsinfecdis.2c00217.
38. Rizvi ZA, Babele P, Sadhu S, Madan U, Tripathy MR, Goswami S, Shailendra Mani, Kumar S, Awasthi A, Dikshit M. Prophylactic treatment of *Glycyrrhiza glabra* mitigates COVID-19 pathology through inhibition of pro-inflammatory cytokines in the hamster model and NETosis. **Frontiers in Immunology**, **2022**. doi.org/10.3389/fimmu.2022.945583.

39. Binayke A, Zaheer A, Dandotiya Y, Kumar Y, Mani S, Madan U, Tripathy MR, Gupta SK, Shrivastava T, Rathore DK, Pandey AK, Awasthi A. Proinflammatory innate cytokines and metabolomic signatures predict T cell response in active COVID-19. **Vaccine** 2022. doi.org/10.3390/vaccines10101762.
40. Thuluva S, Paradkar V, Turaga K, Gunneri SR, Yerroju V, Mogulla R, Suneetha PV, Kyasani M, Manoharan SK, Adabala S, Javvadi AS, Medigeshi G, Singh J, Shaman H, Binayke A, Zaheer A, **Awasthi A**, Singh C, Rao AV, Basu I, Khobragade AK, Pandey AK. Immunogenic superiority and safety of Biological E's CORBEVAX™ vaccine compared to COVISHIELD™ (ChAdOx1 nCoV-19) vaccine studied in a phase III, single blind, multicenter, randomized clinical trial. medRxiv, doi: <https://doi.org/10.1101/2022.03.20.22271891>. under advanced revision **E-Biomedicine**.
41. Rizvi ZA, Sadhu S, Dandotiya J, Sharma P, Singh V, Das V, Kumar R, Samal S, Kalia M, **Awasthi A**. SARS-CoV-2 and its variants, but not Omicron, induce thymic atrophy and impaired T cell development. 2022, submitted. <https://doi.org/10.1101/2022.04.07.487556>.
42. Roy SS, Sharma S, Rizvi ZA, Sinha D, Gupta D, Rophina M, Sehgal P, Maiti S, Scaria V, Sivasubbu S, **Awasthi A**, Harshan KH, Jain S, Chowdhury S. Anti-COVID-19 Activity of FDA Approved Drug through RNA G-quadruplex Binding. **Submitted biorxiv**. <https://doi.org/10.1101/2022.05.31.493843>.
43. Subhash Thuluva, Vikram Paradkar, SubbaReddy Gunneri, Vijay Yerroju, Rammohan Reddy Mogulla, Pothakamuri Venkata Suneetha, Kishore Turaga, Mahesh Kyasani, Senthil Kumar Manoharan, Srikanth Adabala, Aditya Sri Javvadi, Guruprasad Medigeshi, Janmejaya Singh, Heena Shaman, Akshay Binayke, Aymaan Zaheer, **Awasthi A**, Manish Narang, Pradeep Nanjappa, Niranjana Mahantshetti, Bishan Swarup Garg, Anil Kumar Pandey. Safety, tolerability and immunogenicity of Biological E's CORBEVAX™ vaccine in children and adolescents: A prospective, randomised, double-blind, placebo controlled, phase-2/3 study. **Vaccine** 2022, doi.org/10.1016/j.vaccine.2022.10.045.
44. Ramachandran T, Rizvi ZA, Sreevatsan R, Deepika Rathna Murugesan, Mudita Gosain, Dandotiya J, **Ayushi A**, Sweetie S, Pandey AK, Nitya Wadhwa, Shinjini Bhatnagar, Amit Awasthi, Pramod Kumar Garg. Clinical and experimental evidence suggest omicron SARS-CoV-2 is inherently less pathogenic than delta independent of previous immunity. **Submitted, Research Square** 2022. DOI: <https://doi.org/10.21203/rs.3.rs-2258374/v1>.
45. Thuluva S, Paradkar V, Gunneri S, Yerroju V, Mogulla R, Pothakamuri SV, Turaga K, Kyasani M, Manoharan S, Adabala S, Javvadi AS, Medigeshi GR, Singh J, Shaman H, Binayke A, Aymaan Z, **Awasthi A**, Narang M, Pradeep N, Mahantshetti N, Garg BS, Ravi M. Safety, tolerability and immunogenicity of Biological Es CORBEVAX vaccine in children and adolescents: A Prospective, Randomised, Double-blind, Placebo controlled, Phase-2/3 Study. **Vaccine** 2022, doi: <https://doi.org/10.1101/2022.04.20.22274076>.
46. Parray HA, Narayanan N, Garg S, Rizvi ZA, Shrivastava T, Kushwaha S, Singh J, Murugavelu P, Anbalagan A, Mehdi F, Raj N, Singh S, Dandotiya J, Lukose A, Jamwal D, Kumar S, Chiranjivi A, Dhyani S, Mishra N, Jakhar K, Sonar S, Panchal AK, Tripathy MR, Ahamed S, Samal S, Mani S, Bhattacharyya S, Das S, Sinha S, Luthra L, Batra G, Sehgal D, Medigeshi G, Sharma C, **Awasthi A\***, Garg PK, Nair DT, Kumar R. A broadly neutralising monoclonal antibody overcomes the mutational landscape of emerging SARS-CoV2 variant of concerns. (\*Co-corresponding author). **PLOS pathogen** 2022. doi:10.21203/rs.3.rs-1431974/v1.
47. Roy, S.S., Sharma, S., Rizvi, Z.A., Sinha, D., Gupta, D., Rophina, M., Sehgal, P., Sadhu, S., Tripathy, M.R., Samal, S. and Maiti, S., 2023. G4-binding drugs, chlorpromazine and prochlorperazine, repurposed against COVID-19 infection in hamsters. **Frontiers in Molecular Biosciences**, 2023 10, p.1133123.
48. Rizvi, Z.A., Babele, P., Madan, U., Sadhu, S., Tripathy, M.R., Goswami, S., Mani, S., Dikshit, M. and Awasthi, A., 2023. Pharmacological potential of Withania somnifera (L.) Dunal and

- Tinospora cordifolia (Willd.) Miers on the experimental models of COVID-19, T cell differentiation, and neutrophil functions. **Frontiers in Immunology** 2023. doi: 10.3389/fimmu.2023.1138215.
49. Khatri, Ritika, Gazala Siddiqui, Srikanth Sadhu, Vikas Maithil, Preeti Vishwakarma, Bharat Lohiya, Abhishek Goswami, Shubbir Ahmed, Amit Awasthi, and Sweetly Samal. "Intrinsic D614G and P681R/H mutations in SARS-CoV-2 VoCs Alpha, Delta, Omicron and viruses with D614G plus key signature mutations in spike protein alters fusogenicity and infectivity. **Medical Microbiology and Immunology**, 2023. doi: 10.1007/s00430-022-00760-7.
50. Sadhu S, Dalal R, Dandotia J, Binayke A, Vinayak KV, Shakti K, Singh V, Goswami S, Tripathy MR, Rizvi ZA, **Awasthi A**. IL-9 exacerbates SARS-CoV2 infection and associated airway inflammation. Manuscript ID: NCOMMS-22-28241C, **Nature Communication** 2023.
51. Ansari S, Gupta N , Verma R , Singh O , Gupta J , Kumar a ,Yadav M , Binayke A ,Tiwari M, Periwal N, Sood V , Mani S, **Awasthi A** , Shalimar ,Nayak B , Ranjith CT, Surjit M.K, Antiviral activity of the human endogenous retrovirus-R envelope protein against SARS-CoV-2. **Accepted in EMBO reports** 2023, Ref ID- EMBOR-2022-55900V3.
52. Rizvi ZA\*, Sharma K, Srikanth S, Dandotiya J, Khatri R, Singh V, Adhikari N, Das V, Mani S, Samal S, **Awasthi A\***. Omicron sub-lineage BA.5 infection causes attenuated pathology and results in robust protection in Omicron-recovered hACE2 transgenic mice. **Accepted and ahead for publication Communications Biology**, 2023. (ISSN 2399-3642).

Jayanta Bhattacharya

डॉ. जयंत भट्टाचार्य / Dr. Jayanta Bhattacharya  
कार्यकारी निदेशक / Executive Director  
अतिरिक्त प्रभार / Addl. Charge  
प्रांतीय स्वास्थ्य विज्ञान एवं प्रौद्योगिकी संस्थान  
(भारत के जैव प्रौद्योगिकी विभाग का एक स्वायत्त संस्थान)  
एनसीआर बायोटेक विज्ञान क्लस्टर, फरीदाबाद-121001, हरियाणा, भारत  
Translational Health Science and Technology Institute  
(An Autonomous Institute of the Dept. of Biotechnology, Govt. of India)  
NCR Biotech Science Cluster, Faridabad-121001, Haryana, India